Study #2025-1291
A Phase 3, randomized, open-label, multicenter study of Amivantamab in addition to Carboplatin and Pembrolizumab, compared to standard of care platinum and Pembrolizumab and 5-FU, in participants with treatment-naïve recurrent/metastatic head and neck squamous cell carcinoma (OrigAMI-5)
MD Anderson Study Status
Enrolling
Treatment Agent
Amivantamab, Pembrolizumab, Carboplatin, 5-Flurouracil, Cisplatin
Description
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). HNSCC is a type of cancer that develops in the head and neck regions, including the outer tissue layer of the mouth and throat. This study will focus on participants with HNSCC who are treatment-naive (have not received prior treatment) in the R/M setting.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Squamous Cell Carcinoma of Head and Neck
Study phase:
Phase III
Physician name:
Renata Ferrarotto
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.